EICHORPublic-registry trials using Umbralisib that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | TG Therapeutics, Inc. | Diffuse Large B-Cell Lymphoma | PHASE2 / PHASE3 | 168 |
| First FDA approval | UKONIQ — February 2021 (application NDA213176, currently held by TG THERAPS) |
| Also known as | UKONIQ |
| Approved applications | 1 |
| Forms & routes | Tablet · Oral |
| Registry-wide use | 35 registered studies all-time · 0 currently recruiting |
Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Diffuse Large B-Cell Lymphoma drugs
← Eichor home · All tracked trials · Diffuse Large B-Cell Lymphoma studies · Weekly briefs
